Krystal Biotech Insider Trading: Suma Krishnan Cuts Stake Slightly

Rhea-AI Filing Summary

Krystal Biotech (KRYS) President of R&D, Director and 10% owner Suma M. Krishnan filed a Form 4 disclosing modest open-market sales executed on 9–10 July 2025 under a Rule 10b5-1 trading plan adopted 12 Sep 2024.

• Shares sold (reporting person): 7,000 common shares at weighted-average prices of $150.14–$151.39.
• Shares sold (spouse): 7,127 shares at $150.07–$151.39 under a separate 10b5-1 plan.
• Total shares disposed: 14,127, representing roughly 0.5% of their combined holdings.
• Remaining ownership: 1,456,711 shares directly; 90,000 via SMK Trust; 50,000 via Krishnan Family Trust; spouse retains 1,525,929 shares.

The transactions slightly reduce insider exposure yet leave the couple with an aggregate stake of about 3.1 million shares, signalling continuing alignment with shareholders. Because the sales were pre-scheduled, they carry limited information about the company’s near-term outlook.

Positive

• Insiders retain a substantial stake (~3.1 million shares), indicating continued commitment to the company.
• Sales executed under pre-existing Rule 10b5-1 plans, reducing concerns about opportunistic timing.

Negative

• Key executive and 10% owner sold 7,000 shares, which some investors may perceive as a bearish signal.
• Spouse sold an additional 7,127 shares, adding to aggregate insider supply during the period.

Insights

Financial Analyst

TL;DR insider sales modest, pre-planned; neutral impact.

The Form 4 shows minor divestments (~0.5% of the insiders’ combined stake) by a key executive at approximately $150 per share. Conducted under long-standing 10b5-1 plans, the trades appear routine rather than opportunistic. The insiders still control more than 3 million shares, maintaining strong economic alignment. While any insider selling can pressure sentiment, the limited size and pre-arranged nature make the disclosure broadly neutral for valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishnan Suma

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2025		S		200(1)	D	$150.139(2)	1,463,511	D
Common Stock	07/10/2025		S		6,500(1)	D	$150.2252(3)	1,457,011	D
Common Stock	07/10/2025		S		300(1)	D	$151.3867(4)	1,456,711	D
Common Stock								90,000	I	By SMK Trust
Common Stock								50,000	I	By Krishnan Family Trust(5)
Common Stock	07/09/2025		S		200(6)	D	$150.07(7)	1,532,856	I	By Spouse(8)
Common Stock	07/10/2025		S		6,627(6)	D	$150.2184(3)	1,526,229	I	By Spouse(8)
Common Stock	07/10/2025		S		300(6)	D	$151.3867(4)	1,525,929	I	By Spouse(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 .

2. The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

4. The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price.

5. Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.

6. The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025.

7. The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price.

8. Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.

Remarks:

	/s/ Suma M. Krishnan	07/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many KRYS shares did Suma Krishnan sell according to the Form 4?

She sold 7,000 common shares on 9–10 July 2025.

What was the average sale price for the reported KRYS insider transactions?

Weighted-average prices ranged from $150.14 to $151.39 per share.

Were the KRYS insider trades made under a 10b5-1 plan?

Yes, both the reporting person and her spouse sold shares under Rule 10b5-1 trading plans adopted on 12 Sep 2024.

How many KRYS shares does Suma Krishnan still own after the sales?

She directly owns 1,456,711 shares and indirectly holds another 140,000 shares through trusts.

What is the spouse’s remaining KRYS share ownership?

Krish S. Krishnan retains 1,525,929 shares following the reported transactions.

Is the insider selling considered material to Krystal Biotech?

Given that only about 0.5% of the combined stake was sold, the impact is viewed as immaterial.